Vaccine-short Africa is hopeful of getting more COVID-19 doses, as a South African pharmaceutical firm is close to being the first in Africa to distribute them for sale across the continent. U.S.-based Johnson & Johnson says it could soon grant a license to Aspen Pharmacare, Africa’s biggest drugmaker, to produce an “African COVID-19 vaccine” called Aspenovax. Aspen Pharmacare will not make its own vaccine but will package and sell the Johnson-produced vaccine as soon as early 2022. The company has a factory in South Africa from where it already distributes the Johnson & Johnson vaccine nationwide. The proposed deal will significantly boost supplies in Africa, which has suffered serious shortages of vaccines, and is facing the spread of the new omicron variant. The World Health Organization said only 3% of Africans are fully vaccinated. Strive Masiyiwa, head of the African Union’s Africa Vaccine Acquisition Task Team, said the deal will make African nations less dependent on Western governments for vaccine supplies.
SOURCE: VOA
More Stories
Pope Francis Condemns “Economic Colonialism” as He Arrives in the DRC
Encouraging Signs that Corruption is being Successfully Tackled in Parts of Africa
Zimbabwe’s Political Leaders have a Remedy for the Collapse of the Capital Harare
Botswana Cashs In
Scientists Discover Substances and Concoctions Ancient Egyptians Used to Mummify
Cutting Out the Schlep of Registering Nigerien Children
Football Transfers are a Million-dollar Market for Africa
Less than a Month Before Voting Day, Frustrations are Growing across Nigeria
SA Ports Could Lose Business as Three Mineral Rich States Opt to Use the Lobito Corridor
Bringing to Life the Countless Human Stories of Namibia’s Genocide
Trends for African Students Seeking Education Abroad
Floods and Landslides Batter Madagascar